Veteran's sight saved after 'black patch' in one eye was diagnosed as a detached retina
Retinal detachment can lead to permanent blindness if not treated quickly. (Source: Daily Express - Health)
Source: Daily Express - Health - February 19, 2023 Category: Consumer Health News Source Type: news
FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness
"The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade."FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2023 Category: Consumer Health News Tags: Internal Medicine News Alert Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date for Nyxol Eye Drops for Reversal of Mydriasis
FARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 13, 2023 Category: Drugs & Pharmacology Source Type: news
New phase III data show Roche ’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared toafliberceptMoreVabysmo patients showed an absence of blood vessel leakage in the retina compared toaflibercept in a pre-specified exploratory endpointIf approved, RVO would be the third indication forVabysmo in addition toneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaBasel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo ® (faricimab) in macular ...
Source: Roche Investor Update - February 10, 2023 Category: Pharmaceuticals Source Type: news
New phase III data show Roche ’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared toafliberceptMoreVabysmo patients showed an absence of blood vessel leakage in the retina compared toaflibercept in a pre-specified exploratory endpointIf approved, RVO would be the third indication forVabysmo in addition toneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaBasel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo ® (faricimab) in macular ...
Source: Roche Media News - February 10, 2023 Category: Pharmaceuticals Source Type: news
Eylea (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
ROP is a leading cause of childhood blindness worldwide
Eylea now approved to treat five retinal conditions caused by ocular angiogenesis
TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2023 Category: Drugs & Pharmacology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
Black, Hispanic Patients Have Worse Outcomes for Retinal Detachment
WEDNESDAY, Feb. 1, 2023 -- Black and Hispanic patients treated surgically for retinal detachment have worse vision results than White patients, according to a study published online Jan. 4 in the Canadian Journal of Ophthalmology.
Jia Xu, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2023 Category: Pharmaceuticals Source Type: news
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
DALLAS, Jan. 30, 2023 -- (Healthcare Sales & Marketing Network) -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the U.S. Food and Drug Administration ... Regenerative Medicine, Ophthalmology, FDA Nanoscope Therapeutics, Stargardt, optogenetic, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 30, 2023 Category: Pharmaceuticals Source Type: news
Eris buys nine derma brands from Glenmark for Rs 340 crore
The nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquired brands include antifungals Onabet, Luligee; topical steroids Halovate, Sorvate, Dosetil and Powercort, demelanising agent Demelan, vitamin-A gels - Aceret. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 18, 2023 Category: Pharmaceuticals Source Type: news
Upstate researcher awarded grant to study retinal diseases
The EMZ Foundation aims to support outstanding investigators at the early stages of their careers who show innovation and promise in vision research. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - January 10, 2023 Category: Universities & Medical Training Tags: News Research Source Type: news
Prolonged screen time may cause retinal detachment - risk of 'blindness' warns expert
Constant exposure to screens may lead to elongation of the retina, and eventually, retinal detachment. (Source: Daily Express - Health)
Source: Daily Express - Health - January 10, 2023 Category: Consumer Health News Source Type: news
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
Funding to fuel company's progress as it drives lead AMD program into the clinic and continues development progress across extensive ophthalmology pipeline
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2023 -- (Healthcare Sales & Marketing Network) -- Perceive ... Biopharmaceuticals, Ophthalmology, Venture Capital Perceive Biotherapeutics, retinal blindness (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 5, 2023 Category: Pharmaceuticals Source Type: news
